Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19
| العنوان: | Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19 |
|---|---|
| المؤلفون: | S. Moiseev, P. Potapov, V. Nadtocheeva, L. Akulkina, M. Brovko, P. Novikov |
| المصدر: | Clinical pharmacology and therapy. 33:51-56 |
| بيانات النشر: | Pharmapress LLC, 2022. |
| سنة النشر: | 2022 |
| الوصف: | Olokizumab is a new humanised monoclonal antibody targeting interleukin 6 ligand. Olokizumab was developed for treatment of rheumatoid arthritis. In Russia, it was also approved for treatment of COVID-19-associated hyperinflammatory syndrome. This article presents two case reports of COVID-19 patients and reviews the indications for olokizumab administration. |
| تدمد: | 0869-5490 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::267661f321a3028a83b41f668bb1902e https://doi.org/10.32756/0869-5490-2022-2-51-56 |
| رقم الأكسشن: | edsair.doi...........267661f321a3028a83b41f668bb1902e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 08695490 |
|---|